Table 4.
Meta-regression results of primary outcome indicators of each targeted small-molecule drug
| Outcome indicators | Intervention measures | Dose (MD/RR(95%CI)) |
Course (MD/RR(95%CI)) |
|---|---|---|---|
| SRI-4 response | Baricitinib | 0.21 (-7.87, 5.70) | -0.21 (-0.61, 0.21) |
| Deucravacitinib | -0.28 (-8.63, 3.61) | 0.76 (-9.04, 21.90) | |
| Evobrutinib | -0.37 (-2.11, 1.12) | -2.63 (-28.21, 8.44) | |
| Fenebrutinib | 0.02 (-0.65, 0.71) | -0.29 (-10.93, 6.41) | |
| Iberdomide | 0.04 (-9.22, 17.68) | 0.72 (-9.28, 10.93) | |
| BICLA response | Baricitinib | 0.27 (-5.25, 6.81) | -0.06 (-0.47, 0.35) |
| Deucravacitinib | -0.51 (-6.04, 3.16) | 0.41 (-7.12, 11.44) | |
| Fenebrutinib | -0.54 (-2.79, 1.16) | 0.31 (-6.48, 9.64) | |
| Adverse reactions | Baricitinib | 0.11 (-7.71, 7.34) | -0.44 (-1.06, 0.18) |
| Cenerimod | 0.75 (-12.39, 14.43) | 0.29 (-15.12, 12.64) | |
| Deucravacitinib | -2.24 (-15.03, 5.90) | -1.31 (-10.18, 5.44) | |
| Evobrutinib | -0.32 (-3.41, 2.63) | -0.64 (-8.74, 5.15) | |
| Fenebrutinib | -1.57 (-5.47, 1.63) | -0.46 (-8.92, 6.75) | |
| Filgotinib | 0.57 (-6.22, 9.51) | -2.25 (-38.65, 12.87) | |
| GSK2586184 | -0.52 (-1.81, 0.69) | 0.76 (-6.33, 13.21) | |
| Iberdomide | 0.97 (-4.88, 10.19) | -2.29 (-6.35, 0.90) | |
| Lanraplenib | 0.31 (-17.59, 21.22) | 0.43 (-13.30, 12.55) |